TR200102411T2 - Nikotin bağımlılığının önlenmesi ve tedavisi için hapten-taşıyıcı konjugatlar. - Google Patents

Nikotin bağımlılığının önlenmesi ve tedavisi için hapten-taşıyıcı konjugatlar.

Info

Publication number
TR200102411T2
TR200102411T2 TR2001/02411T TR200102411T TR200102411T2 TR 200102411 T2 TR200102411 T2 TR 200102411T2 TR 2001/02411 T TR2001/02411 T TR 2001/02411T TR 200102411 T TR200102411 T TR 200102411T TR 200102411 T2 TR200102411 T2 TR 200102411T2
Authority
TR
Turkey
Prior art keywords
nicotine
prevention
treatment
conjugates
nicotine addiction
Prior art date
Application number
TR2001/02411T
Other languages
English (en)
Turkish (tr)
Inventor
Ennifar Sofiane
Ibrahim Fattom Ali
B. Naso Robert
Original Assignee
Nabi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22747358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200102411(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nabi filed Critical Nabi
Publication of TR200102411T2 publication Critical patent/TR200102411T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y10S436/816—Alkaloids, amphetamines, and barbiturates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Addiction (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TR2001/02411T 1998-12-01 1999-12-01 Nikotin bağımlılığının önlenmesi ve tedavisi için hapten-taşıyıcı konjugatlar. TR200102411T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/201,800 US6232082B1 (en) 1998-12-01 1998-12-01 Hapten-carrier conjugates for treating and preventing nicotine addiction

Publications (1)

Publication Number Publication Date
TR200102411T2 true TR200102411T2 (tr) 2002-01-21

Family

ID=22747358

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02411T TR200102411T2 (tr) 1998-12-01 1999-12-01 Nikotin bağımlılığının önlenmesi ve tedavisi için hapten-taşıyıcı konjugatlar.

Country Status (26)

Country Link
US (7) US6232082B1 (https=)
EP (3) EP1512414A1 (https=)
JP (2) JP4971542B2 (https=)
KR (1) KR100656836B1 (https=)
CN (2) CN100586481C (https=)
AT (1) ATE279211T1 (https=)
AU (1) AU763001B2 (https=)
BR (1) BR9915852A (https=)
CA (1) CA2352765C (https=)
DE (1) DE69921178T2 (https=)
DK (1) DK1135166T3 (https=)
EA (1) EA004956B1 (https=)
ES (1) ES2229800T3 (https=)
HK (2) HK1042428B (https=)
HU (1) HUP0104365A3 (https=)
IL (2) IL143474A0 (https=)
ME (1) MEP34208A (https=)
MX (1) MXPA01005511A (https=)
NO (1) NO331998B1 (https=)
NZ (1) NZ512103A (https=)
PL (1) PL199253B1 (https=)
PT (1) PT1135166E (https=)
RS (1) RS51273B (https=)
TR (1) TR200102411T2 (https=)
WO (1) WO2000032239A1 (https=)
ZA (1) ZA200104477B (https=)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032316A1 (en) * 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US6232082B1 (en) * 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
WO2002058635A2 (en) * 2001-01-26 2002-08-01 The Scripps Research Institute Nicotine immunogens and antibodies and uses thereof
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US20030148260A1 (en) * 2001-08-07 2003-08-07 Bernard Levin Method of diagnosing colorectal adenomas and cancer using proton maggnetic resonance spectroscopy
US20050089524A1 (en) * 2002-03-01 2005-04-28 Sanderson Sam D. Compositions and compounds for use as molecular adjuvant for a nicotine vaccine
NZ537003A (en) * 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
US20040115244A1 (en) * 2002-12-17 2004-06-17 Holgate Eric Jamison Methods and compositions for nicotine replacement therapy
ES2285233T3 (es) 2002-12-20 2007-11-16 Niconovum Ab Un material en particulas que contiene nicotina y celulosa microcristalina fisicamente y quimicamente estable.
WO2005040338A2 (en) * 2003-05-21 2005-05-06 The Scripps Research Institute Constrained alkaloid immunogens and antibodies and uses thereof
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
US7220842B2 (en) * 2004-04-05 2007-05-22 Dade Behring Inc. Immunoassays for buprenorphine and norbuprenorphine
US7678551B2 (en) * 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US20060252107A1 (en) * 2005-02-22 2006-11-09 Acucela, Inc. Compositions and methods for diagnosing and treating retinal diseases
EP1963308A4 (en) * 2005-11-28 2010-12-15 Nabi Biopharmaceuticals METHOD FOR PRODUCING A NICOTINE HAPTEN
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
WO2007100755A1 (en) * 2006-02-27 2007-09-07 Nabi Biopharmaceuticals Method for decreasing the toxic effects of nicotine on fetuses in pregnant women
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition
ES2776100T3 (es) * 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
EP1849780A1 (en) * 2006-04-21 2007-10-31 De Staat der Nederlanden, vert. door de minister van VWS Vaccine against nicotine addiction
EP1854478A1 (en) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
US20110052697A1 (en) * 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
WO2007150030A2 (en) * 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US20100144845A1 (en) * 2006-08-04 2010-06-10 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124634A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
WO2008124632A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
EP2630966B1 (en) 2007-10-12 2017-04-19 Massachusetts Institute of Technology Vaccine nanotechnology
EP2222702B1 (en) * 2007-11-29 2016-01-13 Cytos Biotechnology AG Human monoclonal nicotine specific antibodies
EP2065398A1 (en) * 2007-11-29 2009-06-03 Cytos Biotechnology AG Human monoclonal nicotine specific antibodies
US20110086063A1 (en) * 2008-06-04 2011-04-14 Cornell University Vaccines for prevention and treatment of addiction
JP2011524521A (ja) * 2008-06-13 2011-09-01 ナビ バイオファーマシューティカルズ 喫煙停止キットおよび方法
US20110182918A1 (en) * 2008-06-13 2011-07-28 Nabi Biopharmaceuticals Personalized drug treatment and smoking cessation kit and method
JP2011530497A (ja) * 2008-08-08 2011-12-22 ノバルティス アーゲー ニコチン由来ハプテンの調製方法
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
HUE027823T2 (hu) 2008-12-09 2016-11-28 Coley Pharm Group Inc Immunstimuláló oligonukleotidok
US20110064750A1 (en) * 2009-07-31 2011-03-17 Nabi Biopharmaceuticals Method and kit for treating nicotine addiction
CN107617110A (zh) * 2009-08-26 2018-01-23 西莱克塔生物科技公司 诱导t细胞辅助的组合物
EP2477974A2 (en) * 2009-09-14 2012-07-25 The Scripps Research Institute Nicotine haptens, immunoconjugates and their uses
US20110182831A1 (en) * 2010-01-25 2011-07-28 Aradigm Corporation Systems and methods used in conjunction with nicotine vaccines for effecting cessation of tobacco use
ES2887335T3 (es) 2010-03-17 2021-12-22 Univ Cornell Vacuna contra las drogas de abuso basada en adenovirus alterado
WO2011123042A1 (en) * 2010-04-01 2011-10-06 Independent Pharmaceutica Ab Vaccination procedure and products for use therein
GB201006324D0 (en) 2010-04-15 2010-06-02 Glaxosmithkline Biolog Sa Vaccine
AU2011258165B2 (en) 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
TWI578997B (zh) 2010-06-04 2017-04-21 輝瑞疫苗有限責任公司 用於預防或治療菸鹼成癮之共軛體
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
WO2012099717A1 (en) * 2011-01-04 2012-07-26 National Jewish Health Leukotrienes and asthma exacerbation risk
CN103826657A (zh) 2011-04-04 2014-05-28 衣阿华大学研究基金会 改进疫苗免疫原性的方法
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
WO2013130393A1 (en) 2012-02-28 2013-09-06 Cornell University Aav-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
US10004811B2 (en) * 2012-04-13 2018-06-26 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
TWI600905B (zh) * 2012-09-21 2017-10-01 國立臺灣師範大學 聚合半抗原成為免疫原的技術方法
US9303013B2 (en) 2014-05-16 2016-04-05 Pfizer Inc. Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction
US20170107275A1 (en) * 2014-05-19 2017-04-20 The Scripps Research Institute Enantiopure haptens for nicotine vaccine development
CN104402992B (zh) * 2014-11-28 2018-09-18 杭州安旭科技有限公司 一种合成大麻抗原的合成方法及合成大麻抗原的应用
EP3247380A1 (en) * 2015-01-20 2017-11-29 Universiteit Antwerpen Neuregulin in the treatment of fibrotic disorders
CN106496309A (zh) * 2016-11-24 2017-03-15 北京开景基因技术有限公司 微球抗原及其制备方法以及抗可替宁抗体的制备方法
AU2018283973B2 (en) 2017-06-11 2025-04-24 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
US11440970B2 (en) 2017-08-15 2022-09-13 Antidote Therapeutics, Inc. Nicotine-binding antibodies
CN108362891B (zh) * 2017-12-27 2020-09-25 北京勤邦生物技术有限公司 一种泼尼松的磁免疫化学发光检测试剂盒及其应用
US11333372B2 (en) 2018-03-09 2022-05-17 Scot Matthew Duncan Energy recovery high efficiency dehumidification system
US12571547B2 (en) 2018-03-09 2026-03-10 Heds Holdings Llc Hybrid geothermal, air source, water source systems
EP3801594A1 (en) * 2018-06-06 2021-04-14 Antidote Therapeutics, Inc. Methods for improving circulation and treating cardiovascular disease
KR102237349B1 (ko) 2019-10-23 2021-04-07 한국과학기술연구원 니코틴 중독 또는 금단 증상 예방 또는 치료용 약학 조성물
US20220265601A1 (en) * 2021-02-10 2022-08-25 David Alan Heldreth, JR. Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses.
CN115583992B (zh) * 2022-11-02 2026-02-17 江南大学 一种氧化还原响应的载体蛋白及其在制备疫苗中的应用
CN116747315A (zh) * 2023-06-20 2023-09-15 中国科学院长春应用化学研究所 高dar值的抗体-免疫调节药物偶联物及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4375414A (en) 1971-05-20 1983-03-01 Meir Strahilevitz Immunological methods for removing species from the blood circulatory system and devices therefor
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US3888886A (en) 1972-06-08 1975-06-10 Mobil Oil Corp Oxidation of alkanes to maleic anhydride using promoted vanadium-phosphorus catalyst
US4045420A (en) 1973-05-29 1977-08-30 Syva Company Non-oxo-carbonyl containing benzoyl ecgonine and cocaine compounds polypeptide and derivatives thereof
US3888866A (en) 1973-06-01 1975-06-10 Syva Co Nitrogen derivatives of benzoyl ecgonine
US4053459A (en) 1975-09-24 1977-10-11 Hoffmann-La Roche Inc. Antibody specific to methaqualone and its metabolites
US4235864A (en) 1978-04-10 1980-11-25 Research Corporation Simultaneous radio immunoassay of multiple antigens and _assay for cocaine metabolites
US4376825A (en) 1979-05-07 1983-03-15 Syva Company Enzyme amplification compounds for assays for androgens
US4666837A (en) 1982-05-24 1987-05-19 Smithkline-Rit DNA sequences, recombinant DNA molecules and processes for producing the A and B subunits of cholera toxin and preparations containing so-obtained subunit or subunits
SU1123704A1 (ru) 1983-04-08 1984-11-15 Научно-Исследовательский Институт По Биологическим Испытаниям Химических Соединений Способ получени конъюгированных антигенов
EP0194158A3 (en) 1985-03-08 1988-02-24 Baylor College of Medicine Anti-nicotine and anti-cotinine antibodies (monoclonal and other), and their uses in nicotine and cotinine assays
US5019384A (en) 1986-06-30 1991-05-28 Massachusetts Institute Of Technology Immunonodulating compositions and their use
US4791067A (en) 1987-06-25 1988-12-13 Fisher Scientific Co. Agglutination immunoassay for hapten involving monoclonal antibody of IgA class reagent
DE3884731D1 (de) 1987-10-09 1993-11-11 Ube Industries Monoklonaler Antikörper gegen Methamphetamin, seine Herstellung, Testverfahren und Testsatz für Methamphetamin.
US5268276A (en) 1988-09-16 1993-12-07 Jan Holmgren Recombinant systems for expression of cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
EP0363041A1 (en) 1988-09-21 1990-04-11 Ube Industries, Ltd. Monoclonal antibody to morphine, preparation of monoclonal antibody, assaying kit and assaying method of morphine
GB9001694D0 (en) 1990-01-25 1990-03-28 Therapeutic Antibodies Inc Immunogenic compositions
CH678394A5 (https=) 1990-08-22 1991-09-13 Cerny Erich H
US5674978A (en) 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US5290784A (en) * 1991-07-18 1994-03-01 Yueqian Qu Aconitane derivatives used as a medication to treat addiction
US5233042A (en) 1991-12-16 1993-08-03 Biosite Diagnostics, Inc. Cocaine derivatives
US5283066A (en) 1992-02-19 1994-02-01 Development Center For Biotechnology Method of stimulating an immune response by using a hapten
DE4216133A1 (de) 1992-05-15 1993-11-18 Bissendorf Peptide Gmbh Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen
WO1993023076A1 (en) 1992-05-20 1993-11-25 The Johns-Hopkins University Alternative receptor therapy
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
EP0613899B1 (en) 1993-03-04 2003-01-15 Matsushita Electric Industrial Co., Ltd. Cocaine derivative, protein conjugate thereof, monoclonal antibody producing hybridoma cell line, method for preparing the hybridoma cell line and monoclonal antibody
US5375414A (en) 1993-10-04 1994-12-27 Ford Motor Company Automotive engine exhaust aftertreatment system including hydrocarbon adsorber with internal engine purge flow control
EP0756629A1 (en) 1994-04-08 1997-02-05 Immunologic Pharmaceutical Corporation Pharmaceutical formulations for treating japanese cedar pollen allergy
US5510102A (en) 1995-01-23 1996-04-23 The Regents Of The University Of California Plasma and polymer containing surgical hemostatic adhesives
DK1329226T3 (da) 1995-03-31 2007-09-24 Xenova Res Ltd Haptenbærerkonjugater til anvendelse i behandling af stofmisbrug
US5840307A (en) 1995-03-31 1998-11-24 Immulogic Pharmacuetical Corp. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation
US5876727A (en) 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
JP2001516567A (ja) * 1997-09-19 2001-10-02 セレックス， インコーポレイテッド 抗原の免疫原性および抗体の特異性を改善する方法
US6232082B1 (en) * 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction

Also Published As

Publication number Publication date
JP2011079849A (ja) 2011-04-21
CN1768861A (zh) 2006-05-10
DE69921178D1 (de) 2004-11-18
EP1512414A1 (en) 2005-03-09
HK1091415A1 (zh) 2007-01-19
NO331998B1 (no) 2012-05-21
EA200100610A1 (ru) 2002-04-25
AU763001B2 (en) 2003-07-10
US6518031B2 (en) 2003-02-11
CA2352765A1 (en) 2000-06-08
US20050136047A1 (en) 2005-06-23
US20030165950A1 (en) 2003-09-04
PT1135166E (pt) 2005-01-31
US20080026000A1 (en) 2008-01-31
DE69921178T2 (de) 2005-11-17
HUP0104365A3 (en) 2002-05-28
PL349012A1 (en) 2002-06-17
US6773891B2 (en) 2004-08-10
ZA200104477B (en) 2002-01-16
CN1329508A (zh) 2002-01-02
HK1042428B (en) 2005-07-29
AU2033500A (en) 2000-06-19
PL199253B1 (pl) 2008-08-29
CA2352765C (en) 2011-02-15
ES2229800T3 (es) 2005-04-16
US20110217320A1 (en) 2011-09-08
EP1135166B9 (en) 2005-02-02
MEP34208A (en) 2011-02-10
IL143474A (en) 2006-06-11
EP1135166A1 (en) 2001-09-26
KR20010090854A (ko) 2001-10-19
ATE279211T1 (de) 2004-10-15
RS51273B (sr) 2010-12-31
HK1043061B (zh) 2006-07-07
JP4971542B2 (ja) 2012-07-11
CN100586481C (zh) 2010-02-03
US8026109B2 (en) 2011-09-27
US6232082B1 (en) 2001-05-15
WO2000032239A9 (en) 2002-08-22
CN1220521C (zh) 2005-09-28
HK1043061A1 (en) 2002-09-06
HK1042428A1 (en) 2002-08-16
MXPA01005511A (es) 2004-08-19
EP2324855A1 (en) 2011-05-25
NO20012589D0 (no) 2001-05-25
BR9915852A (pt) 2004-06-29
US7247502B2 (en) 2007-07-24
EA004956B1 (ru) 2004-10-28
HUP0104365A2 (hu) 2002-04-29
US20020004208A1 (en) 2002-01-10
NZ512103A (en) 2003-09-26
IL143474A0 (en) 2002-04-21
DK1135166T3 (da) 2005-02-14
EP1135166B1 (en) 2004-10-13
KR100656836B1 (ko) 2006-12-12
NO20012589L (no) 2001-07-20
US20110002957A1 (en) 2011-01-06
YU39601A (sh) 2003-10-31
US7776620B2 (en) 2010-08-17
WO2000032239A1 (en) 2000-06-08
JP2002531421A (ja) 2002-09-24

Similar Documents

Publication Publication Date Title
TR200102411T2 (tr) Nikotin bağımlılığının önlenmesi ve tedavisi için hapten-taşıyıcı konjugatlar.
BR9711580A (pt) Conjugados hapteno-veìculo para uso em terapia contra uso indiscriminado de drogas e métodos para preparação destes
UA88599C2 (ru) Коньюгат производное калихеамицина-антитело, способ его получения и способы лечения
ATE369878T1 (de) Träger-pharmaka-konjugate
CY1117729T1 (el) Μεθοδοι για την παρασκευη κυτταροτοξικων συζευγματων μεϋτανσινοειδων και παραγοντων δεσμευσης κυτταρου
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
ATE472338T1 (de) Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
TR199700213A2 (xx) 2-Aril s�bstit�entli piridinler.
BG103251A (bg) Оксадиазоли, методи за получаването им и приложението им като лекарствени средства
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
WO2003089593A3 (en) Adjuvant enhanced immunotherapy
WO1999050303A3 (en) Immune response modulator alpha-2 macroglobulin complex
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
PT814843E (pt) Conjugados de hapteno-transportador para utilizacao na terapia de abuso de drogas
ATE198834T1 (de) Konjugate bestehend aus polysaccharid und protein
ATE280588T1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
ATE94764T1 (de) Nasal applizierbares arzneimittel, verfahren zu seiner herstellung und seine verwendung.
DK0992512T3 (da) Reduceret cortisolkonjugat
DE50114335D1 (de) Lh-rh-antagonisten, deren herstellung und verwendung als arzneimittel
DE602005015855D1 (de) Verfahren zur herstellung von immunogenen konjugaten
DK101196A (da) Histaminderivat, histamin-immunogen-konjugat samt antistof fremstillet mod konjugatet
MXPA02012015A (es) Ligandos de receptores para integrinas.
ATE265234T1 (de) Pharmazeutische zusammensetzung von hydrophob modifizierten hedgehog-proteinen und deren verwendung
UY26420A1 (es) Procedimiento mejorado para la preparación de derivados bencimidazol adecuados como fármacos antiulcerosos, particularmente omeprazol o pantoprazol
ECSP003736A (es) Procedimiento mejorado para la preparacion de derivados de bencimidazol adecuados como farmacos antiulcerosos, particularmente omeprazol o pantoprazol